被称为银屑病性疾病的牛皮癣和银屑病性关节炎（PsA）是免疫介导性炎症性疾病，患者表现出皮肤和肌骨炎症状。约影响全球总人口的2-3％，尽管当前存在免疫调节治疗，但牛皮癣和PsA仍存在未满足的治疗需求。因此，患有银屑病性疾病的患者常常体验到生活质量下降。最近，小分子药物类别，通常被研究作为抗癌药物，称为组蛋白去乙酰化酶（HDAC）抑制剂，已被提出作为一种新的、有前途的抗炎治疗方法，用于免疫和炎症相关疾病。在炎症性疾病中，目前的证据来自于像类风湿性关节炎（RA）和系统性红斑狼疮（SLE）这样的疾病的研究，虽然有一些研究关于牛皮癣，但尚无针对PsA患者的数据。在本综述中，我们简要介绍了银屑病性疾病、牛皮癣和PsA，以及HDACs，并讨论了使用HDAC抑制剂管理持续性炎症的潜在理论，以建议其在银屑病性疾病中的可能使用。

Collectively known as psoriatic disease, psoriasis and psoriatic arthritis (PsA) are immune-mediated inflammatory diseases in which patients present with cutaneous and musculoskeletal inflammation. Affecting roughly 2-3% of the world's total population, there remains unmet therapeutic needs in both psoriasis and PsA despite the availability of current immunomodulatory treatments. As a result, patients with psoriatic disease often experience reduced quality of life. Recently, a class of small molecules, commonly investigated as anti-cancer agents, called histone deacetylase (HDAC) inhibitors, have been proposed as a new promising anti-inflammatory treatment for immune- and inflammatory-related diseases. In inflammatory diseases, current evidence is derived from studies on diseases like rheumatoid arthritis (RA) and systematic lupus erythematosus (SLE), and while there are some reports studying psoriasis, data on PsA patients are not yet available. In this review, we provide a brief overview of psoriatic disease, psoriasis, and PsA, as well as HDACs, and discuss the rationale behind the potential use of HDAC inhibitors in the management of persistent inflammation to suggest its possible use in psoriatic disease.